Evidence map›Paper›PMID 41329757›Full record

ArticlePLoS pathogens2025

Monocyte-eosinophil signaling axis promotes vaccine-mediated protection against SARS-CoV-2.

Kathryn M Moore, Stephanie L Foster, Meenakshi Kar, Katharine A Floyd, Elizabeth J Elrod, M Elliott Williams, Jacob Vander Velden, Madison Ellis, Ansa Malik, Bushra Wali and 9 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kathryn M MooreEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.
Stephanie L FosterEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.
Meenakshi KarEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.
Katharine A FloydEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.
Elizabeth J ElrodEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.
M Elliott WilliamsDepartment of Microbiology and Immunology, Emory University; Atlanta, GeorgiaUnited States of America.
Jacob Vander VeldenEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.
Madison EllisEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.
Ansa MalikEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.
Bushra WaliEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.
Stacey LappEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.
Amanda MetzEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.
Steven E BosingerEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.
Vineet D MenacheryCenter for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Robert A SederVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Rama Rao AmaraEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.
Jacob E KohlmeierDepartment of Microbiology and Immunology, Emory University; Atlanta, GeorgiaUnited States of America.
Arash GrakouiEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.
Mehul S SutharEmory Vaccine Center, Emory National Primate Research Center, Emory UniversityAtlanta, GeorgiaUnited States of America.ORCID 0000-0002-2686-8380

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00017 · NIAID · EMORY UNIVERSITY · PI LOWEN, ANICE · 2021 to 2025
$27.3M
Coordination of innate and cellular mucosal immunity in SARS-CoV-2 clearanceR01AI188896 · NIAID · EMORY UNIVERSITY · PI JACOB E KOHLMEIER, Mehul Shamal Suthar · 2025 to 2026
$1.4M
NIAID NIH HHS 75N93021C00017NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI188896NIH HHS HHSN272201400004CNIH HHS P51 OD011132
6 · The paper itself

Abstract

COVID-19 vaccines provide robust protection against severe disease, hospitalization, and death. Neutralizing antibodies are a strong correlate of protection and can prevent SARS-CoV-2 infection of the lungs. We used a conventional laboratory mouse model combined with high- or low-dose vaccination to understand the early immunological response following SARS-CoV-2 infection in the lungs of vaccinated mice. The lungs of high-dose vaccinated mice were completely protected against SARS-CoV-2 infection whereas low-dose vaccinated mice were partially protected. We observed a greater influx of total monocytes, macrophages, dendritic cells, neutrophils, and eosinophils in the lungs of low-dose vaccinated mice compared to naïve infected mice. The different proportions of innate immune cells in the lungs indicated that infection in low-dose vaccinated mice induces a unique inflammatory environment compared to naïve infected or uninfected mice. A prominent feature of infection of low-dose vaccinated mice was infiltration of eosinophils in the lungs, which we observed across different COVID-19 vaccines and SARS-CoV-2 variants. Single cell transcriptional profiling of lung parenchymal immune cells showed that viral RNA was predominantly associated with eosinophils. Eosinophils from low-dose vaccinated mice were transcriptionally distinct from naïve mice after challenge and showed an IFN-γ biased signature. Further, monocytes from low-dose vaccinated mice expressed eotaxin-2, suggesting a monocyte-eosinophil signaling axis. Antibody mediated depletion of eosinophils in low-dose vaccinated mice resulted in increased virus replication and dissemination in the lungs. These findings demonstrate the protective nature of eosinophils during SARS-CoV-2 infection in the context of vaccination and highlight quantitative and qualitative differences in the immune response in a model for vaccine breakthrough infection.

Indexed as

COVID-19COVID-19 VaccinesEosinophilsMonocytesSARS-CoV-2AnimalsAntibodies, NeutralizingAntibodies, ViralFemaleLungMiceMice, Inbred C57BLSignal TransductionAntibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccines

Identifiers

PMID41329757
PMCPMC12688131

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.